SynCore Biotechnology (Taiwan) Today
SynCore Biotechnology is selling for under 34.85 as of the 31st of January 2025; that is 0.14 percent decrease since the beginning of the trading day. The stock's lowest day price was 34.85. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Valuation
Check how we calculate scores
SynCore Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. SynCore Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding SynCore Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board | ChihWen Lee |
| Thematic Idea | Biotech (View all Themes) |
| Business Concentration | Biotech, Biotechnology, Healthcare (View all Sectors) |
SynCore Biotechnology Co (4192) is traded on Taiwan OTC Exchange in Taiwan and employs 65 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SynCore Biotechnology's market, we take the total number of its shares issued and multiply it by SynCore Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. SynCore Biotechnology operates under Healthcare sector and is part of Biotechnology industry. The entity has 115.08 M outstanding shares.
SynCore Biotechnology Co has accumulated about 380.81 M in cash with (229.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57.
Check SynCore Biotechnology Probability Of Bankruptcy
SynCore Biotechnology Risk Profiles
Although SynCore Biotechnology's alpha and beta are two of the key measurements used to evaluate SynCore Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
SynCore Stock Against Markets
SynCore Biotechnology Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with SynCore Biotechnology stock to make a market-neutral strategy. Peer analysis of SynCore Biotechnology could also be used in its relative valuation, which is a method of valuing SynCore Biotechnology by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
SynCore Biotechnology Corporate Management
Elected by the shareholders, the SynCore Biotechnology's board of directors comprises two types of representatives: SynCore Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SynCore. The board's role is to monitor SynCore Biotechnology's management team and ensure that shareholders' interests are well served. SynCore Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SynCore Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChiaHao Liang | Senior Manager of Finance & Accounting | Profile | |
| MuhHwan Su | General Manager | Profile | |
| WenHsin Huang | VP Department | Profile | |
| FernFang Lin | VP Devel | Profile | |
| CharnJung Chang | General Manager-Ophthalmology Project | Profile | |
| HuiHung MBA | VP Drugs | Profile |
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.